尼可地尔对微血管性心绞痛患者hsCRP、sCD40L水平的影响及临床疗效

摘要

Objective :To explore influence of nicorandil on plasma levels of high sensitive C reactive protein (hsCRP) and soluble T cell CD40 ligand (sCD40L) and therapeutic effect of nicorandil in patients with microvascular angina pectoris .Methods :A total of 102 patients with microvascular angina pectoris were enrolled ,randomly and equally divided into routine treatment group (received routine comprehensive treatment ) and nicorandil group (received nic-orandil based on routine comprehensive treatment ,5mg ,3 times/d) ,both groups were treated for eight weeks . Plasma levels of hsCRP and sCD40L were measured and compared between two groups before and eight weeks after treatment ,and therapeutic effect was compared between two groups .Results : Compared with before treatment there were significant reductions in plasma levels of hsCRP and sCD 40L in both groups after eight weeks ;compared with routine treatment group after treatment ,there were significant reductions in plasma levels of hsCRP [ (2.63 ± 0.25) mg/L vs.(1.80 ± 0.28) mg/L] and sCD40L [ (71.88 ± 3.71) pg/ml vs .(55.25 ± 2.47) pg/ml] in nicorandil group , P＝0. 001 all.Total effective rate of nicorandil group was significantly higher than that of routine treatment group (78.43% vs.56.86%,P＝0.02).Conclusion :Nicorandil can significantly rise clinical effect ,reduce plasma levels of hsCRP and sCD40L in patients with microvascular angina pectoris .%目的:探讨尼可地尔对微血管性心绞痛患者血浆高敏 C反应蛋白(hsCRP ) 、可溶性 T细胞 CD40配体(sCD40L)水平的影响及临床疗效.方法:入选微血管性心绞痛患者102例,随机均分为常规治疗组(进行常规综合治疗)和尼可地尔组(在常规综合治疗基础上加用尼可地尔, 5mg , 3次/d) ,治疗8周.治疗前及治疗8周后测定两组患者血浆hsCRP 、 sCD40L水平,并对两组患者临床疗效进行比较.结果: 8周后,与治疗前比较,两组血浆hsCRP 、 sCD40L水平均明显下降,且与常规治疗组比较,尼可地尔组患者血浆hsCRP [(2.63 ± 0.25) mg/L比(1.80 ± 0.28) mg/L]、sCD40L[(71.88 ± 3.71)pg/ml比(55.25 ± 2.47) pg/ml]水平降低更显著(P均＝0.001).尼可地尔组总有效率明显高于常规治疗组(78. 43% 比56.86%,P＝0. 02) .结论:尼可地尔可显著提高微血管性心绞痛患者的临床疗效,而且能降低患者的血浆炎症因子高敏C反应蛋白、可溶性T细胞CD40配体的水平.